BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1347 related articles for article (PubMed ID: 27443740)

  • 1. Replication fork stability confers chemoresistance in BRCA-deficient cells.
    Ray Chaudhuri A; Callen E; Ding X; Gogola E; Duarte AA; Lee JE; Wong N; Lafarga V; Calvo JA; Panzarino NJ; John S; Day A; Crespo AV; Shen B; Starnes LM; de Ruiter JR; Daniel JA; Konstantinopoulos PA; Cortez D; Cantor SB; Fernandez-Capetillo O; Ge K; Jonkers J; Rottenberg S; Sharan SK; Nussenzweig A
    Nature; 2016 Jul; 535(7612):382-7. PubMed ID: 27443740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency.
    Cong K; Peng M; Kousholt AN; Lee WTC; Lee S; Nayak S; Krais J; VanderVere-Carozza PS; Pawelczak KS; Calvo J; Panzarino NJ; Turchi JJ; Johnson N; Jonkers J; Rothenberg E; Cantor SB
    Mol Cell; 2021 Aug; 81(15):3128-3144.e7. PubMed ID: 34216544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PCAF-Mediated Histone Acetylation Promotes Replication Fork Degradation by MRE11 and EXO1 in BRCA-Deficient Cells.
    Kim JJ; Lee SY; Choi JH; Woo HG; Xhemalce B; Miller KM
    Mol Cell; 2020 Oct; 80(2):327-344.e8. PubMed ID: 32966758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
    Bryant HE; Schultz N; Thomas HD; Parker KM; Flower D; Lopez E; Kyle S; Meuth M; Curtin NJ; Helleday T
    Nature; 2005 Apr; 434(7035):913-7. PubMed ID: 15829966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deletion of BRCA2 exon 27 causes defects in response to both stalled and collapsed replication forks.
    Kim TM; Son MY; Dodds S; Hu L; Hasty P
    Mutat Res; 2014; 766-767():66-72. PubMed ID: 25847274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CtIP-Mediated Fork Protection Synergizes with BRCA1 to Suppress Genomic Instability upon DNA Replication Stress.
    Przetocka S; Porro A; Bolck HA; Walker C; Lezaja A; Trenner A; von Aesch C; Himmels SF; D'Andrea AD; Ceccaldi R; Altmeyer M; Sartori AA
    Mol Cell; 2018 Nov; 72(3):568-582.e6. PubMed ID: 30344097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumours.
    Dibitetto D; Liptay M; Vivalda F; Dogan H; Gogola E; González Fernández M; Duarte A; Schmid JA; Decollogny M; Francica P; Przetocka S; Durant ST; Forment JV; Klebic I; Siffert M; de Bruijn R; Kousholt AN; Marti NA; Dettwiler M; Sørensen CS; Tille JC; Undurraga M; Labidi-Galy I; Lopes M; Sartori AA; Jonkers J; Rottenberg S
    Nat Commun; 2024 May; 15(1):4430. PubMed ID: 38789420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. WRN helicase safeguards deprotected replication forks in BRCA2-mutated cancer cells.
    Datta A; Biswas K; Sommers JA; Thompson H; Awate S; Nicolae CM; Thakar T; Moldovan GL; Shoemaker RH; Sharan SK; Brosh RM
    Nat Commun; 2021 Nov; 12(1):6561. PubMed ID: 34772932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells.
    Gottipati P; Vischioni B; Schultz N; Solomons J; Bryant HE; Djureinovic T; Issaeva N; Sleeth K; Sharma RA; Helleday T
    Cancer Res; 2010 Jul; 70(13):5389-98. PubMed ID: 20551068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stalled replication forks within heterochromatin require ATRX for protection.
    Huh MS; Ivanochko D; Hashem LE; Curtin M; Delorme M; Goodall E; Yan K; Picketts DJ
    Cell Death Dis; 2016 May; 7(5):e2220. PubMed ID: 27171262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cockayne syndrome group B protein regulates fork restart, fork progression and MRE11-dependent fork degradation in BRCA1/2-deficient cells.
    Batenburg NL; Mersaoui SY; Walker JR; Coulombe Y; Hammond-Martel I; Wurtele H; Masson JY; Zhu XD
    Nucleic Acids Res; 2021 Dec; 49(22):12836-12854. PubMed ID: 34871413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of E2F7 confers resistance to poly-ADP-ribose polymerase (PARP) inhibitors in BRCA2-deficient cells.
    Clements KE; Thakar T; Nicolae CM; Liang X; Wang HG; Moldovan GL
    Nucleic Acids Res; 2018 Sep; 46(17):8898-8907. PubMed ID: 30032296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mre11-dependent degradation of stalled DNA replication forks is prevented by BRCA2 and PARP1.
    Ying S; Hamdy FC; Helleday T
    Cancer Res; 2012 Jun; 72(11):2814-21. PubMed ID: 22447567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RADX Modulates RAD51 Activity to Control Replication Fork Protection.
    Bhat KP; Krishnamoorthy A; Dungrawala H; Garcin EB; Modesti M; Cortez D
    Cell Rep; 2018 Jul; 24(3):538-545. PubMed ID: 30021152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
    Oplustilova L; Wolanin K; Mistrik M; Korinkova G; Simkova D; Bouchal J; Lenobel R; Bartkova J; Lau A; O'Connor MJ; Lukas J; Bartek J
    Cell Cycle; 2012 Oct; 11(20):3837-50. PubMed ID: 22983061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies.
    Ding X; Ray Chaudhuri A; Callen E; Pang Y; Biswas K; Klarmann KD; Martin BK; Burkett S; Cleveland L; Stauffer S; Sullivan T; Dewan A; Marks H; Tubbs AT; Wong N; Buehler E; Akagi K; Martin SE; Keller JR; Nussenzweig A; Sharan SK
    Nat Commun; 2016 Aug; 7():12425. PubMed ID: 27498558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARPi focus the spotlight on replication fork protection in cancer.
    Schlacher K
    Nat Cell Biol; 2017 Oct; 19(11):1309-1310. PubMed ID: 29087384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MRE11 and EXO1 nucleases degrade reversed forks and elicit MUS81-dependent fork rescue in BRCA2-deficient cells.
    Lemaçon D; Jackson J; Quinet A; Brickner JR; Li S; Yazinski S; You Z; Ira G; Zou L; Mosammaparast N; Vindigni A
    Nat Commun; 2017 Oct; 8(1):860. PubMed ID: 29038425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deletion of BRCA2 exon 27 causes defects in response to both stalled and collapsed replication forks.
    Kim TM; Son MY; Dodds S; Hu L; Hasty P
    Mutat Res; 2014; 766-767():66-72. PubMed ID: 25773776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.
    Yazinski SA; Comaills V; Buisson R; Genois MM; Nguyen HD; Ho CK; Todorova Kwan T; Morris R; Lauffer S; Nussenzweig A; Ramaswamy S; Benes CH; Haber DA; Maheswaran S; Birrer MJ; Zou L
    Genes Dev; 2017 Feb; 31(3):318-332. PubMed ID: 28242626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 68.